Midostaurin domestic launch progress in 2024

Midostaurin (English common nameMidostaurin), a kinase inhibitor targeting FLT3 gene mutations and other targets, has shown significant efficacy in the treatment of acute myeloid leukemia and systemic mastocytosis. However, until May 2024, this drug has not yet received marketing approval in the Chinese market.

Factors affecting its domestic listing may include:

1. Drug approval process: New drugs need to go through strict clinical trials and approval, which is a time-consuming process.

2. Market demand: Although the drug has significant efficacy, market demand may also affect the speed of launch.

It is worth noting that my country’s approval policy for innovative drugs is constantly being optimized, paving the way for midostaurin to be launched in the country in the future.

For patients who are in urgent need of this medicine, they may currently need to purchase it through regular overseas channels. Please pay attention to ensure the authenticity of the medicine. Overseas, midostaurin is available in two versions: original drug and generic version, with different prices, and patients can choose according to their own conditions. Specifically, the Indian version of the original drug produced by Novartis, with specifications of 25mg*28 pills, is priced at about more than 3,000 yuan per box; while the generic drug launched by India's BDR Pharmaceuticals, with the same specifications, is sold at about more than 2,000 yuan per box. This price difference provides patients with more choices.

In addition, as a prescription drug, you must consult a professional doctor before using midostaurin. It is mainly used to treat newly diagnosed adult patients with FLT3 mutation-positive acute myeloid leukemia, as well as aggressive systemic mastocytosis. It is necessary to strictly follow the doctor's instructions when using it, and conduct regular inspections to ensure that the medication is safe and effective.

In general, although midostaurin is not currently on the market in China, with the improvement of approval policies and the increase in market demand, this drug is expected to enter the domestic market in the future, bringing new treatment options to patients.